Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03744793 · ClinicalTrials.gov registry record · Phase 2

Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer

A Phase 2 study of Metastatic Urothelial Carcinoma and Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 2
Development phase
18
Enrollment target
1
Study location

NCT03744793: Active Phase 2 study of Metastatic Urothelial Carcinoma and Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, sponsored by M.D. Anderson Cancer Center.

NCT03744793 is a Phase 2 study of Metastatic Urothelial Carcinoma and Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 18 participants, below the 130-participant average among 30 other Metastatic Urothelial Carcinoma trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03744793, a Phase 2 study of Metastatic Urothelial Carcinoma and Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

This phase II trial studies how well pemetrexed and avelumab work in treating patients with MTAP-deficient urothelial cancer that has spread to other places in the body. Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pemetrexed and avelumab may work better in treating patients with MTAP-deficient urothelial cancer.

Primary Outcome

Will be defined as the number of subjects with a best response of complete response or partial response at any protocol evaluation by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria divided by the total numbers of subjects receiving their first dose of trial therapy.

Conditions Studied

Metastatic Urothelial Carcinoma Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation MTAP Negative

Interventions

  • DRUG Pemetrexed
  • DRUG Avelumab

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2019-04-11
Est. Completion 2027-01-31
Phase Phase 2
M.D. Anderson Cancer Center

2,692 total trials

What the registry record for NCT03744793 still lists

NCT03744793 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 130-participant average among 30 other Metastatic Urothelial Carcinoma trials with a reported enrollment target (86% lower).

The record links to 7 conditions, with Metastatic Urothelial Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pemetrexed is the first listed.

NCT03744793 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT03744793 about?

NCT03744793 is a clinical study titled "Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer". This phase II trial studies how well pemetrexed and avelumab work in treating patients with MTAP-deficient urothelial cancer that has spread to other places in the body. Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclona...

What is the current status of trial NCT03744793?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2019-04-11. Estimated completion is 2027-01-31.

What conditions does trial NCT03744793 study?

This clinical trial studies the following conditions: Metastatic Urothelial Carcinoma, Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant.

What interventions are being tested in trial NCT03744793?

The interventions under investigation include: Pemetrexed (DRUG), Avelumab (DRUG).

Who is sponsoring clinical trial NCT03744793?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03744793 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Urothelial Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03744793's enrollment target sits among peer trials

18 26th of 30 higher than 5 of 30 other Metastatic Urothelial Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Urothelial Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01245179 · 18 participants · Phase 1

    Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease

  • NCT01999361 · 18 participants · NA

    Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss

  • NCT02359825 · 18 participants · Phase 1

    Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function

  • NCT02870244 · 18 participants · Phase 1

    Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03744793, the US trial registry maintained by the National Library of Medicine. NCT03744793 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.